Drug Profile
ARGX 111
Alternative Names: Anti-cMet SIMPLE Antibody; ARGX-111Latest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator arGEN-X
- Developer argenx
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in South Korea (Parenteral)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in Belgium (Parenteral)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in France (Parenteral)